JP2024547112A - Ｇｌｐ－１受容体作動薬の結晶形及びその調製方法 - Google Patents
Ｇｌｐ－１受容体作動薬の結晶形及びその調製方法 Download PDFInfo
- Publication number
- JP2024547112A JP2024547112A JP2024537982A JP2024537982A JP2024547112A JP 2024547112 A JP2024547112 A JP 2024547112A JP 2024537982 A JP2024537982 A JP 2024537982A JP 2024537982 A JP2024537982 A JP 2024537982A JP 2024547112 A JP2024547112 A JP 2024547112A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- methyl
- powder
- ray diffraction
- chloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111586541 | 2021-12-23 | ||
| CN202111586541.3 | 2021-12-23 | ||
| PCT/CN2022/141407 WO2023116879A1 (zh) | 2021-12-23 | 2022-12-23 | 一种glp-1受体激动剂的结晶形式及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024547112A true JP2024547112A (ja) | 2024-12-26 |
| JP2024547112A5 JP2024547112A5 (enExample) | 2026-05-08 |
Family
ID=86901327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024537982A Pending JP2024547112A (ja) | 2021-12-23 | 2022-12-23 | Ｇｌｐ－１受容体作動薬の結晶形及びその調製方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250049778A1 (enExample) |
| EP (2) | EP4455140B1 (enExample) |
| JP (1) | JP2024547112A (enExample) |
| KR (1) | KR20240125004A (enExample) |
| CN (1) | CN118401518A (enExample) |
| AU (1) | AU2022422997A1 (enExample) |
| CA (1) | CA3241677A1 (enExample) |
| MX (1) | MX2024007907A (enExample) |
| TW (1) | TW202328115A (enExample) |
| WO (1) | WO2023116879A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024340407A1 (en) | 2023-09-14 | 2026-04-23 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025109387A1 (en) | 2023-11-24 | 2025-05-30 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025189141A1 (en) | 2024-03-08 | 2025-09-12 | Annapurna Bio, Inc. | Methods for treating obesity and increasing weight loss |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10934279B2 (en) * | 2018-06-13 | 2021-03-02 | Pfizer Inc. | GLP-1 receptor agonists and uses thereof |
| JP2023528565A (ja) * | 2020-04-01 | 2023-07-05 | ハンジョウ ジョンメイ フアドン ファーマシューティカル シーオー．，エルティーディー． | Ｇｌｐ－１受容体アゴニストの結晶形ａおよびその調製法 |
| PL4157832T3 (pl) * | 2020-05-27 | 2024-12-16 | Qilu Regor Therapeutics Inc. | Sól i postacie krystaliczne agonistów GLP-1R oraz ich zastosowania |
| CN119930605A (zh) * | 2020-09-01 | 2025-05-06 | 江苏恒瑞医药股份有限公司 | 稠合咪唑类衍生物、其制备方法及其在医药上的应用 |
| WO2022228490A1 (zh) * | 2021-04-30 | 2022-11-03 | 上海翰森生物医药科技有限公司 | 多环类衍生物调节剂、其制备方法和应用 |
-
2022
- 2022-12-23 JP JP2024537982A patent/JP2024547112A/ja active Pending
- 2022-12-23 US US18/722,345 patent/US20250049778A1/en active Pending
- 2022-12-23 KR KR1020247024148A patent/KR20240125004A/ko active Pending
- 2022-12-23 MX MX2024007907A patent/MX2024007907A/es unknown
- 2022-12-23 AU AU2022422997A patent/AU2022422997A1/en active Pending
- 2022-12-23 CN CN202280084770.1A patent/CN118401518A/zh active Pending
- 2022-12-23 CA CA3241677A patent/CA3241677A1/en active Pending
- 2022-12-23 WO PCT/CN2022/141407 patent/WO2023116879A1/zh not_active Ceased
- 2022-12-23 EP EP22910190.2A patent/EP4455140B1/en active Active
- 2022-12-23 EP EP26159633.2A patent/EP4725484A2/en active Pending
- 2022-12-23 TW TW111149828A patent/TW202328115A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240125004A (ko) | 2024-08-19 |
| CN118401518A (zh) | 2024-07-26 |
| EP4455140B1 (en) | 2026-04-01 |
| US20250049778A1 (en) | 2025-02-13 |
| EP4455140A1 (en) | 2024-10-30 |
| EP4725484A2 (en) | 2026-04-15 |
| EP4455140A4 (en) | 2025-04-09 |
| CA3241677A1 (en) | 2023-06-29 |
| TW202328115A (zh) | 2023-07-16 |
| WO2023116879A1 (zh) | 2023-06-29 |
| AU2022422997A1 (en) | 2024-07-11 |
| MX2024007907A (es) | 2024-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024547113A (ja) | Ｇｌｐ－１受容体作動薬の薬学的に許容される塩、結晶形及びその調製方法 | |
| EP4455140B1 (en) | Crystalline forms of a glp-1 receptor agonist and preparation methods therefor | |
| EP4332102A1 (en) | Isoquinolone compound and use thereof | |
| TW202220962A (zh) | 選擇性NaV抑制劑的結晶形式及其製備方法 | |
| EP4403555A1 (en) | Substituted 1,4-dihydro-1,6-naphthyridine amide and use thereof | |
| KR20250116731A (ko) | 갑상선 호르몬 β 수용체 작용제, 그 결정형, 제조 방법 및 용도 | |
| US20240374581A1 (en) | Salt types of tricyclic tetrahydro isoquinoline derivative | |
| US20250361226A1 (en) | Pharmaceutically acceptable salt of benzo[c]chroman compound and polymorphic form and use of pharmaceutically acceptable salt | |
| TWI914461B (zh) | 一種吲唑類衍生物的藥學上可接受鹽、結晶形式及其製備方法 | |
| CN112500353B (zh) | 一种左西孟旦的前药化合物、制备方法及其应用 | |
| TW202408504A (zh) | 噻吩[2,3-d]咪唑類化合物的鹽及其晶型和在醫藥上的用途 | |
| TW202333694A (zh) | 稠環衍生物的晶型、其製備方法及其應用 | |
| EP4610257A1 (en) | Crystal form of isoquinolinone compound and preparation method therefor | |
| WO2023151660A1 (zh) | 一种p2x3受体拮抗剂的结晶形式及其制备方法 | |
| CN114644616B (zh) | 一种吲唑类衍生物的药学上可接受的盐、结晶形式及其制备方法 | |
| WO2024179558A1 (zh) | Pirtobrutinib的晶型及其制备方法和用途 | |
| WO2025011618A9 (zh) | 噻唑并吡嗪类化合物的盐或其结晶及其应用 | |
| CN120535504A (zh) | 一种p38α-MK2抑制剂的晶型及其制备方法和应用 | |
| EP3974421A1 (en) | Crystal form of pyrimidine sulfonamide compound and preparation method therefor | |
| WO2026082108A1 (zh) | 一种nlrp3抑制剂用于治疗帕金森病或帕金森综合征的用途 | |
| WO2026017039A1 (zh) | Glp-1受体激动剂化合物的盐、晶型、制备方法及其药物组合物和用途 | |
| WO2022095930A1 (zh) | Atx抑制剂氘代衍生物及其应用 | |
| WO2021175225A1 (zh) | 三环类化合物及其应用 | |
| WO2021023271A1 (zh) | 作为前列环素受体激动剂的化合物的晶型及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240627 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251223 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20251223 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260408 |